In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso)

Journal de Mycologie Medicale

Volumn 27, Issue 4, 2017, Pages 469-475

  Zida, A ^a,b,c   Yacouba, A ^a,d   Bamba, S ^c,e   Sangare, I ^c,e   Sawadogo, M ^a,b   Guiguemde, T ^b,f   Kone, S ^a   Traore, L K ^b   Ouedraogo Traore, R ^b,f   Guiguemde, R T ^b,c  

^a CENTRE HOSPITALIER UNIVERSITAIRE YALGADO OUÉDRAOGO   (Burkina Faso)

^b Université Joseph KI ZERBO   (Burkina Faso)

^c Polytechnic University of Bobo Dioulasso   (Burkina Faso)

^d Ecole Privée de Santé Sciences Nouvelles Centre Médical des Sciences Nouvelles   (Burkina Faso)

^e Centre Hospitalier Universitaire Souro Sanou   (Burkina Faso)

^f Centre Hospitalier Universitaire Pediatrique Charles de Gaulle   (Burkina Faso)

Author keywords

Antifungal agents; Burkina Faso; Candida albicans; Cross resistance; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CHLORAMPHENICOL; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BURKINA FASO; CANDIDA ALBICANS; CHLAMYDOSPORE; CROSS RESISTANCE; CROSS-SECTIONAL STUDY; DISK DIFFUSION; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; NONHUMAN; UNIVERSITY HOSPITAL; ADULT; CANDIDIASIS; CHEMISTRY; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; THRUSH; URINE; VAGINA CANDIDIASIS;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BURKINA FASO; CANDIDA ALBICANS; CANDIDIASIS; CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 85025592871     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2017.07.001     Document Type: Article

References (33)

1. Alfouzan, W., Dhar, R., Ashkanani, H., Gupta, M., Rachel, C., Khan, Z.U., Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait. J Mycol Med 25 (2015), 23–28.
2. Eksi, F., Gayyurhan, E.D., Balci, I., In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method. Sci World J, 2013, 2013 236903.
3. Lockhart, S.R., Current epidemiology of Candida Infection. Clin Microbiol Newsl 36 (2014), 131–136.
4. Pu, S., Niu, S., Zhang, C., Xu, X., Qin, M., Huang, S., et al. Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China. J Microbiol Immunol Infect, 2015 [pii: S1684-1182(15)00029-8].
5. Goldman, G.H., da Silva Ferreira, M.E., dos Reis Marques, E., Savoldi, M., Perlin, D., Park, S., et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 50 (2004), 25–32.
6. Razzaghi-Abyaneh, M., Sadeghi, G., Zeinali, E., Alirezaee, M., Shams-Ghahfarokhi, M., Amani, A., et al. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. J Mycol Med 24 (2014), e43–e50.
7. Rodloff, A., Koch, D., Schaumann, R., Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 16 (2011), 187–195.
8. Wabe, N.T., Hussein, J., Suleman, S., Abdella, K., In vitro antifungal susceptibility of Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. Retrovirology, 9, 2012, 44.
9. Zhang, L., Zhou, S., Pan, A., Li, J., Liu, B., Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis 33 (2015), 1–4.
10. Choukri, F., Benderdouche, M., Sednaoui, P., In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. J Mycol Med 24 (2014), 303–307.
11. Kalkanci, A., Berk, E., Aykan, B., Caglar, K., Hizel, K., Arman, D., et al. Epidemiology and antifungal susceptibility of Candida species isolated from hospitalized patients. J Mycol Med 17 (2007), 16–20.
12. National Committee for Clinical Laboratory Standards, Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard M44-A. 2004, National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Clinical and Laboratory Standards Institute, Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts; 17th informational supplement, CLSI M44-S2. 2007, Clinical and Laboratory Standards Institute, Wayne, PA.
14. Bamba, S., Ouedraogo, A.S., Sangare, I., Zida, A., Cisse, M., Karou, D.S., et al. Digestive fungal flora in asymptomatic subjects in Bobo-Dioulasso, Burkina Faso. Asian Pac J Trop Biomed 4 (2014), 659–662.
15. Holland, J., Young, M.L., Lee, O., Chen, S.C.A., Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 79 (2003), 249–250.
16. Monroy-Pérez, E., Paniagua-Contreras, G.L., Rodríguez-Purata, P., Vaca-Paniagua, F., Vázquez-Villaseñor, M., Díaz-Velásquez, C., et al. High virulence and antifungal resistance in clinical strains of Candida albicans. Can J Infect Dis Med Microbiol, 2016, 2016, 5930489.
17. Zarei Mahmoudabadi, A., Zarrin, M., Beheshti Fard, M., Antifungal susceptibility of Candida species isolated from candidura. J Microbiol 6 (2012), 24–28.
18. Zarei Mahmoudabadi, A., Zarrin, M., Kiasat, N., Biofilm formation and susceptibility to amphotericin B and fluconazole in Candida albicans. J Microbiol, 7, 2014, e28057.
19. Yenisehirli, G., Bulut, N., Yenisehirli, A., Bulut, Y., In vitro susceptibilities of Candida albicans isolates to antifungal agents in Tokat, Turkey. J Microbiol, 8, 2015, e28057.
20. Cartledge, J.D., Midgley, J., Gazzard, B.G., Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS 11 (1997), 1839–1844.
21. Lass-Florl, C., The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52 (2009), 197–205.
22. MasiaCanuto, M., Gutierrez Rodero, F., Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2 (2002), 550–563.
23. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from orofaringeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol 201;4:19–26.
24. e éd., 2014 183 pp.
25. Haddadi, P., Zareifar, S., Badiee, P., Alborzi, A., Mokhtari, M., Zomorodian, K., et al. Yeast colonization and drug susceptibility pattern in the pediatric patients with neutropenia. J Microbiol, 7(9), 2014, 11858.
26. De Paula, S.B., Morey, A.T., Santos, J.P., dos Santos, P.M.C., Gameiro, D.G., Kerbauy, G., et al. Oral Candida colonization in HIV-infected patients in Londrina-PR, Brazil: antifungal susceptibility and virulence factors. J Infect Dev Ctries 9 (2015), 1350–1359.
27. Mukasa, K.J., Herbert, I., Daniel, A., Sserunkuma, K.L., Joel, B., Frederick, B., Antifungal susceptibility patterns of vulvovaginal Candida species among women attending antenatal clinic at Mbarara Regional Referral Hospital, South Western Uganda. Br Microbiol Res J 5 (2015), 322–331.
28. Ghannoum, M.A., Rice, L.B., Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12 (1999), 501–517.
29. Liu, J.-Y., Shi, C., Wang, Y., Li, W.-J., Zhao, Y., Xiang, M.-J., Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China. Res Microbiol 166 (2015), 153–161.
30. Liu, X.P., Fan, S.R., Peng, Y.T., Zhang, H.P., Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. J Mycol Med 24 (2014), 106–111.
31. Müller, F.-M.C., Weig, M., Peter, J., Walsh, T.J., Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 46 (2000), 338–341.
32. Stevens, D.A., Stevens, J.A., Cross-resistance phenotypes of fluconazole-resistant Candida species: results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis 26 (1996), 145–148.
33. Zhang, X., Liu, Z.H., 25 S rDNA genotype and antifungal susceptibility of vaginal Candida albicans. Zhonghua Fu Chan Ke Za Zhi 51:4 (2016), 279–288.